Loading...
XNYSAIM
Market cap10mUSD
Dec 27, Last price  
0.21USD
1D
3.63%
1Q
-25.61%
Jan 2017
-99.31%
Name

AIM ImmunoTech Inc

Chart & Performance

D1W1MN
XNYS:AIM chart
P/E
—
P/S
49.92
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
117.23%
Rev. gr., 5y
-11.26%
Revenues
202k
+43.26%
1,229,0001,083,000933,0001,059,000265,000111,000135,000161,000213,000150,000197,000133,00092,000437,000367,000140,000163,000135,000141,000202,000
Net income
-29m
L+37.35%
-24,140,000-13,213,000-19,399,000-18,139,000-12,219,000-13,438,000-13,136,000-9,015,000-17,354,000-16,225,000-17,450,000-15,230,000-7,502,000-8,259,000-9,813,000-10,826,000-16,258,000-21,513,000-21,086,000-28,962,000
CFO
-21m
L+32.03%
-7,240,000-7,236,000-13,747,000-15,112,000-9,358,000-9,297,000-11,886,000-10,096,000-13,136,000-16,830,000-13,918,000-16,053,000-7,380,000-7,941,000-10,640,000-9,067,000-10,368,000-13,965,000-16,108,000-21,267,000
Earnings
Mar 31, 2025

Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
URL
https://aimimmuno.com/
IPO date
Jul 12, 1996
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
202
43.26%
141
4.44%
135
-17.18%
Cost of revenue
32,118
39,987
17,194
Unusual Expense (Income)
NOPBT
(31,916)
(39,846)
(17,059)
NOPBT Margin
Operating Taxes
1,641
2,386
Tax Rate
NOPAT
(31,916)
(41,487)
(19,445)
Net income
(28,962)
37.35%
(21,086)
-1.98%
(21,513)
32.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
485
80
13,042
BB yield
-2.27%
-0.53%
-29.95%
Debt
Debt current
446
178
37
Long-term debt
1,213
1,496
261
Deferred revenue
(23,711)
Other long-term liabilities
(29,431)
35
Net debt
(11,411)
(1,967)
(22,954)
Cash flow
Cash from operating activities
(21,267)
(16,108)
(13,965)
CAPEX
(271)
(633)
Cash from investing activities
(832)
10,988
(631)
Cash from financing activities
485
80
8,188
FCF
(30,768)
(37,954)
(17,815)
Balance
Cash
13,070
34,190
48,268
Long term investments
(30,549)
(25,016)
Excess cash
13,060
3,634
23,245
Stockholders' equity
(408,770)
(379,802)
(360,338)
Invested Capital
419,945
389,676
393,690
ROIC
ROCE
EV
Common stock shares outstanding
48,585
48,047
47,340
Price
0.44
41.04%
0.31
-66.10%
0.92
-48.60%
Market cap
21,373
42.62%
14,986
-65.59%
43,553
-23.59%
EV
10,651
13,715
21,314
EBITDA
(31,678)
(39,590)
(16,284)
EV/EBITDA
Interest
478
67
Interest/NOPBT